Jay Grobler, Executive Director of Infectious Disease and Vaccines Discovery, Preclinical, and Early Development (DPED) at Merck Research Laboratories describes “Molnupiravir: A broad spectrum antiviral for the treatment of COVID-19.” Molnupiravir is an experimental therapy for SARS-CoV-2 that operates through a mechanism called viral error catastrophe.

Part of the NIBR Science of Therapeutics Symposium on Coronavirus Antivirals, June 8, 2021. Content presented by external speakers not affiliated with Novartis are responsible for their own content and do not speak on behalf of Novartis.

©2021 Novartis AG

свернуть